BCM
RCUS icon

BlueCrest Capital Management’s Arcus Biosciences RCUS Stock Holding History

BlueCrest Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,474
Closed -$316K – 1759
2018
Q1 		$316K Buy
+20,474
New +$341K 0.01% 1019

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlueCrest Capital Management's RCUS Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2018, closing a stake of 20,474 shares — an estimated $316K sold.

BlueCrest Capital Management first reported a position in RCUS in Q1 2018 and held it in 1 quarter. The position peaked at $316K in Q1 2018. 64 funds tracked by Wall St. Rank hold RCUS as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Arcus Biosciences position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 20,474 Arcus Biosciences shares in Q2 2018, an estimated $316K.
  • BlueCrest Capital Management first reported a position in Arcus Biosciences in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Arcus Biosciences position peaked at $316K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.